| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.04. | AZ claims another win for Imfinzi in frontline liver cancer | ||
| 02.04. | Threat of Trump's pharma tariffs looms again | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | ||
| 01.04. | Lilly bags FDA okay for Wegovy pill rival orforglipron | ||
| 01.04. | DNA testing can help right racial imbalance in breast cancer | ||
| 01.04. | EMA seeks input on virtual alternative to animal test | ||
| 01.04. | Agios mulls early FDA filing for sickle cell therapy | ||
| 01.04. | FDA points to liver injury with Amgen's Tavneos | ||
| 01.04. | NHS to offer Wegovy to a million more people in England | ||
| 31.03. | Novo hits back at rivals with cut-price Wegovy subscriptions | ||
| 31.03. | Biogen swoops on Apellis with $5.6bn offer | ||
| 31.03. | Eli Lilly makes $7.8bn takeover play for Centessa | ||
| 31.03. | UCB brings first therapy for rare disease TK2d to EU | ||
| 31.03. | AZ considers filings for long-acting Strensiq follow-up | ||
| 31.03. | Blackstone closes record $6.3bn life sciences fund | ||
| 30.03. | Obesity-focused biotech Kailera joins IPO queue in US | ||
| 30.03. | One in four diabetics has undiagnosed heart failure; study | ||
| 30.03. | Amgen's BiTE for lung cancer backed for EU approval | ||
| 27.03. | Recordati gets €10.9bn takeover bid from private equity firm | ||
| 27.03. | Where others missed, AZ's IL-33 drug hits the mark in COPD | ||
| 27.03. | Touchdown for Rocket as its first gene therapy gets US okay | ||
| 27.03. | Novartis snaps up food allergy firm Excellergy for $2bn | ||
| 26.03. | Wave's stock wavers on obesity drug data | ||
| 26.03. | AI predicts liver cancer risk with "high accuracy" | ||
| 26.03. | Corcept gets FDA OK for first-in-class ovarian cancer drug |